Pluvicto

(vipivotide tetraxetan)

12.5 ML lutetium Lu 177 vipivotide tetraxetan 27 MCI/ML Injection [Pluvicto]

NO BLACK BOX WARNING

Dosage & administration

* Select patients for treatment using LOCAMETZ® or an approved PSMA-11 imaging agent based on PSMA expression in tumors.
* Recommended Dosage: Administer 7.4 GBq (200 mCi) every 6 weeks for up to 6 doses.
* Dose interruption, reduction, or permanent discontinuation may be required due to adverse reactions.

biomarker testing

Pluvicto clinical details

Genetic testing requirements were obtained from the NCCN guidelines for each cancer type.

drug label

Pluvicto prescribing information

Contact Medical Science Liaison Report Adverse Event

prior authorization

Pluvicto prior authorization resources

PDFCoverage Authorization Appeals

Learn More

Benefits investigation

PDFAAA PatientCONNECT Pluvicto Enrollment Form

Learn More

financial assistance

Pluvicto financial assistance options

Co-pay savings program

commercial only

PDFAAA PatientCONNECT Pluvicto Enrollment Form

OTHEREnroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Foundation programs

under insured

no insurance

goverment insurance

65+

PDFAAA PatientCONNECT Pluvicto Enrollment Form

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Pluvicto patient education

Getting started on Pluvicto

To share resource; ask patient to:

1.Pull out phone

2.Open camera

3.Scan QR code with camera

4.Tap link